Literature DB >> 1316366

Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.

M E Erwin1, R N Jones.   

Abstract

CI-960, fleroxacin, lomefloxacin, and temafloxacin were tested against over 100 strains of Neisseria gonorrhoeae. Each organism was tested in triplicate by using agar dilution and disk diffusion methods recommended by the National Committee for Clinical Laboratory Standards. CI-960 was the most potent compound, with a MIC against 90% of the strains tested of 0.008 microgram/ml, and the least active was fleroxacin (MIC against 90% of strains, 0.12 microgram/ml). Only the susceptible interpretive category was recommended for the CI-960 tests as follows: 5-micrograms disk, greater than or equal to 39 mm (MIC correlate, less than or equal to 0.12 microgram/ml). Three interpretive categories were proposed for the other fluoroquinolones as follows: fleroxacin, 5-micrograms disk susceptible at greater than or equal to 33 mm (MIC correlate, less than or equal to 0.25 microgram/ml), intermediate at 28 to 32 mm (MIC correlate, 0.5 microgram/ml), and resistant at less than or equal to 27 mm (MIC correlate, greater than 0.5 microgram/ml); lomefloxacin, 10-micrograms disk susceptible at greater than or equal to 35 mm (MIC correlate, less than or equal to 0.12 microgram/ml), intermediate at 28 to 34 mm (MIC correlates, 0.25 to 0.5 microgram/ml), and resistant at less than or equal to 27 mm (MIC correlate, greater than 0.5 microgram/ml); and temafloxacin, 5-micrograms disk susceptible at greater than or equal to 36 mm (MIC correlate, less than or equal to 0.06 microgram/ml), intermediate at 28 to 35 mm (MIC correlates 0.12 to 0.25 microgram/ml), and resistant at less than or equal to 27 mm (greater than 0.25 microgram/ml). Interpretive agreement between disk diffusion results and the MICs was 100% for each agent, with the exception of lomefloxacin, which had a 0.9% minor error. All drugs were stable in GC agar medium for at least 21 days when stored at 2 to 5 degrees C.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316366      PMCID: PMC265244          DOI: 10.1128/jcm.30.5.1170-1173.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Evaluation of the standardized disk diffusion and agar dilution antibiotic susceptibility test methods by using strains of Neisseria gonorrhoeae from the United States and Southeast Asia.

Authors:  S D Putnam; B S Lavin; J R Stone; E C Oldfield; D G Hooper
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.

Authors:  R N Jones; P C Fuchs; J A Washington; T L Gavan; P R Murray; E H Gerlach; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1990 Nov-Dec       Impact factor: 2.803

4.  Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

5.  Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin).

Authors:  K B Lim; V S Rajan; Y C Giam; E O Lui; E H Sng; K L Yeo
Journal:  Br J Vener Dis       Date:  1984-06

6.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

7.  Single dose ciprofloxacin for treating gonococcal infections in men.

Authors:  P S Loo; G L Ridgway; J D Oriel
Journal:  Genitourin Med       Date:  1985-10

8.  Fleroxacin versus standard therapy in gonococcal urethritis.

Authors:  A Lassus; O V Renkonen; J Ellmén
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

9.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  3 in total

Review 1.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

2.  Detection of quinolone-resistant Neisseria gonorrhoeae.

Authors:  K M Kam; P W Wong; M M Cheung; N K Ho
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

3.  Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

Authors:  C J Carlyn; L J Doyle; C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.